Translating these results into clinical usability, in which an understanding of PTH trends is required for the treatment of CKD-MBD, each of the 4 immunoassays that was tested provides reliable longitudinal information that can inform and/or guide treatment decisions. This evidence concerns the gene PTH and Marchiafava-Bignami disease.